---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025462"
form_type: "8-K"
ticker: null
cik: "0001805087"
company_name: "GELESIS HOLDINGS, INC."
filed_at: "2022-11-21T23:59:59+00:00"
generated_at: "2026-06-21T15:10:41.785469+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gelesis receives NYSE delisting notice for market cap and equity below $50M thresholds

## Summary
- Received NYSE notice on Nov 16, 2022 for non-compliance with Section 802.01B: market cap <$50M and equity <$50M over 30-day periods.
- Has 45 days to submit a plan to cure; cure period up to 18 months if plan accepted by NYSE.
- Common stock will continue trading under GLS with .BC designation during cure period.
- Company intends to contact NYSE within 10 days and develop a compliance plan.

## SEC filing metadata
- accession: 0000950170-22-025462
- form_type: 8-K
- cik: 0001805087
- company_name: GELESIS HOLDINGS, INC.
- filed_at: 2022-11-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1805087/000095017022025462/0000950170-22-025462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1805087/000095017022025462/gls-20221116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025462
- JSON: https://secwatch.observer/filing/0000950170-22-025462.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025462.txt

## Key facts
- Listing & Compliance Notices
  GELESIS HOLDINGS, INC. received a nyse deficiency notice notice regarding market value (rules 802.01B).
  - Exchange: nyse
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 802.01B
  source text: November 16, 2022, Gelesis Holdings, Inc. (the “Company”) received a notification letter (the “Notice”) from the New York Stock Exchange (the “NYSE”) advising that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual because its total market capitalization was less than $50 million over a 30 trading-day period and its stockholders’ equity was less than $50 million over a separate 30 trading-day period. The Company’s common stock will continue to be listed and traded on the NYSE during the Cure Period referred to below, subj
  evidence_url: https://www.sec.gov/Archives/edgar/data/1805087/000095017022025462/0000950170-22-025462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.